Central European Journal of Medicine

, Volume 7, Issue 5, pp 591–595 | Cite as

Plasma serotonin level in left-sided colonic diverticulosis: A pilot study

  • Katarzyna Neubauer
  • Małgorzata Krzystek-Korpacka
  • Leszek Paradowski
Research Article


Neurotransmitters might participate in the development of diverticular disease. We measured fasting and postprandial serotonin levels in colonic diverticulosis patients and healthy volunteers. We demonstrated significantly lower maximal concentrations of serotonin in patients than the controls (respectively 109.8±61.4 and 251.3±44.1 ng/ml, p<0.001) as well as lower serotonin minimal values (respectively 38.4±21.8 and 124.6±41.4 ng/ml, p<0.001) and areas under time-course curves (respectively 288.8±139.8 and 739±167.4 ng/ml, p<0.001); significant difference between alternating pattern and normal bowel habit concerning fasting serotonin level, the hormone response to test meal (p=0.041) as well as minimal serotonin level (p=0.044). Bowel habit was also related to peak serotonin values following a test meal with 38.5 ng/ml in constipation, 139.5 ng/ml in diarrhea, 122.4 ng/ml in alternating pattern and 249 ng/ml in subjects with normal bowel habit (p=0.040) as well as AUC with 120.8 ng/ml in constipation, 416 ng/ml in diarrhea, 298 ng/ml in alternating pattern and 684 ng/ml in subjects with normal bowel habit (p=0.043). We demonstrated substantial differences in fasting serum serotonin levels as well as the hormone response to a test meal between colonic diverticulosis patients and healthy individuals, which seemed to be associated with abnormal bowel habits rather than presence of diverticula.


Serotonin Diverticulosis Colon 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Neubauer K., Dudkowiak R., Paradowski L., Leftsided diverticulosis of the large bowel as the second most common abnormality in colonoscopy — review of 425 cases of colonic diverticulosis, Adv. Clin. Exp. Med., 2010, 19, 513–518Google Scholar
  2. [2]
    Nguyen G.C., Sam J., Anand N., Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States, World J. Gastroenterol., 2011, 17, 1600–1605PubMedCrossRefGoogle Scholar
  3. [3]
    Jeyarajah S., Faiz O., Bottle A., Aylin P., Bjarnason I., Tekkis P.P., et al., Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions, Aliment. Pharmacol. Ther., 2009, 30, 1171–1182PubMedCrossRefGoogle Scholar
  4. [4]
    Jeyarajah S., Papagrigoriadis S., Review article: the pathogenesis of diverticular disease — current perspectives on motility and neurotransmitters, Aliment. Pharmacol. Ther., 2011, 33, 789–800PubMedCrossRefGoogle Scholar
  5. [5]
    Sikander A., Rana S.V., Prasad K.K., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin. Chim. Acta., 2009, 403, 47–55PubMedCrossRefGoogle Scholar
  6. [6]
    Banerjee S., Akbar N., Moorhead J., Rennie J.A., Leather A.J., Cooper D., Increased presence of serotonin-producing cells in colons with diverticular disease may indicate involvement in the pathophysiology of the condition, Int. J. Colorectal. Dis., 2007, 6, 643–649CrossRefGoogle Scholar
  7. [7]
    Costedio M.M., Coates M.D., Danielson A.B., Buttolph T.R. 3rd, Blaszyk H.J., Mawe G.M., et al., Serotonin signaling in diverticular disease, J. Gastrointest. Surg., 2008, 12, 1439–1445PubMedCrossRefGoogle Scholar
  8. [8]
    Spiller R., Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease, Neurogastroenterol. Motil., 2007, 19(Suppl. 2), 25–31PubMedCrossRefGoogle Scholar
  9. [9]
    Tan K.Y, Seow-Chowen F., Fiber and colorectal diseases: separating fact from fiction, World J. Gastroenterol., 2007, 13, 4161–4167PubMedGoogle Scholar
  10. [10]
    Spiller R.C.L., Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome, Curr. Opin. Pharmacol., 2011, 11, 68–74PubMedCrossRefGoogle Scholar
  11. [11]
    Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am. J. Gastroenterol., 2009, 104, 1831–1843PubMedCrossRefGoogle Scholar
  12. [12]
    Tursi A., Diverticular disease: a therapeutic overview, World J. Gastrointest. Pharmacol. Ther., 2010, 1, 27–35PubMedCrossRefGoogle Scholar
  13. [13]
    Dunlop S.P., Coleman N.S., Blackshow E., Perkins A.C., Singh G., Mardsen C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 2005, 3, 349–357PubMedCrossRefGoogle Scholar
  14. [14]
    Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A., Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome, Gastroenterology, 2006, 130, 34–43PubMedCrossRefGoogle Scholar
  15. [15]
    Bearcroft C.P., Perrett D., Farthing M.J.G., Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study, Gut, 1998, 42, 42–46PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Katarzyna Neubauer
    • 1
  • Małgorzata Krzystek-Korpacka
    • 2
  • Leszek Paradowski
    • 1
  1. 1.Department of Gastroenterology and HepatologyWroclaw Medical UniversityWroclawPoland
  2. 2.Department of Medical BiochemistryWroclaw Medical UniversityWroclawPoland

Personalised recommendations